Summit Therapeutics (NASDAQ: SMMT): Navigating Financial Challenges with Promising Lung Cancer Drug

• Summit Therapeutics faces a "going concern risk" due to insufficient cash for future operations, despite recent capital raises.
• The biopharmaceutical company reported a wider-than-expected loss of $0.28 per share in the second quarter.
• Positive Phase 3 data for its lead lung cancer therapy, ivonescimab, offers a potential upside, with data submitted to the FDA.

Summit Therapeutics (NASDAQ: SMMT) is a drug development company focused on creating new cancer therapies. Its main drug candidate is ivonescimab, which is in late-stage studies for lung cancer treatment. On July 24, 2026, analyst firm Jefferies lowered its price target for Summit Therapeutics to $15.00 from $17.00, representing a potential 9.65% upside from its price at the time.

The company's financial situation presents challenges. Summit Therapeutics reported a wider-than-expected loss of $0.28 per share for the second quarter. More significantly, the company disclosed a "going concern risk," as highlighted by Benzinga. This means its current cash is not enough to fund planned operations for at least the next year, raising doubts about its ability to continue without new funding.

Despite these concerns, Summit Therapeutics has been actively raising capital. The company holds $690.70 million in cash and short-term investments. It recently raised $230.80 million through an At-The-Market (ATM) facility, which lets a company sell shares to raise money over time. An additional $68.40 million was raised after the quarter ended using the same method.

Positive developments center on its main drug. Summit Therapeutics shared updated Phase 3 data showing improving overall survival trends for its lung cancer therapy, ivonescimab. The company has submitted this new data to the FDA as part of its ongoing Biologics License Application review, which is a formal request to market a new drug.

Summit Therapeutics is also reducing its expenses to manage its cash. Research and development costs fell 24.20% to $157.70 million. As detailed by the Zacks Equity Research Analyst Blog, general and administrative expenses dropped 82.60% to $62.80 million, largely due to a significant decrease in stock-based compensation for employees.